ST-elevation myocardial infarction (STEMI) is an urgent symptom associated with sudden myocardial ischemia and ST segment elevated in ECG. Primary percutaneous coronary intervention (PCI) re-open infarct artery efficiently for STEMI patients. However, patients are readmitted shortly after the primary PCI for several unfavorable clinical outcomes including thrombosis in stent, recurrence of myocardial infarction, stroke, and heart failure. This study is intended to test the predictive ability of a new biomarker soluble ST2 (sST2) in peripheral blood. Previous studies have shown that elevated sST2 is highly associated with unfavorable clinical outcomes of patients with ischemia heart diseases and heart failure. This study will further investigate the ability of sST2 to predict unfavorable outcomes for STEMI patients after primary PCI.
Study Type
OBSERVATIONAL
Enrollment
200
Wuhan Asia Heart Hospital
Wuhan, Hubei, China
stent restenosis
Evidence of stent restenosis of the patients receiving primary PCI, confirmed by coronary angiography when patients are readmitted due to the related symptoms.
Time frame: one year after primary PCI
recurrence of myocardial infarction
Evidence of myocardial infarction of the patients receiving primary PCI, confirmed by coronary angiography or ECG when patients are readmitted due to the related symptoms.
Time frame: one year after primary PCI
heart failure
Evidence of heart failure of the patients receiving primary PCI, confirmed by clinical diagnosis when patients are readmitted due to the related symptoms.
Time frame: one year after primary PCI
cardiac death
Evidence of death due to the cardiac dysfunction of the patients receiving primary PCI.
Time frame: one year after primary PCI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.